Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

123.44 +5.44 (+4.61%)
Streaming Delayed Price Updated: 10:16 AM EST, Jan 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 580,004
Open 119.41
Bid (Size) 123.30 (200)
Ask (Size) 123.60 (500)
Prev. Close 118.00
Today's Range 119.00 - 124.00
52wk Range 81.20 - 126.77
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BNTX Shares Rise On Goldman Sachs Upgrade, Optimism For Cancer Portfolio ↗
Via Stocktwits
News headline image
The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era
Issued on behalf of Oncolytics Biotech Inc. 
From USA News Group
Via GlobeNewswire

Performance

YTD
+27.7%
+27.7%
1 Month
+33.9%
+33.9%
3 Month
+16.2%
+16.2%
6 Month
+7.7%
+7.7%
1 Year
+5.3%
+5.3%

More News

Read More
News headline image
Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot
Via Finterra
Topics Initial Public Offering Intellectual Property
Trump’s Iran Tariff Threat Lit a Fuse Under Oil — and Wall Street Still Sold It ↗
Via Chartmill
Topics Government
News headline image
The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape
Via MarketMinute
Topics Economy Intellectual Property World Trade
News headline image
BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Finalizes CureVac Acquisition: A Strategic Consolidation Met with Market Skepticism
Via MarketMinute
Topics Intellectual Property
News headline image
Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics
Via PredictStreet
Topics Initial Public Offering Intellectual Property
News headline image
Moderna’s Second Act: Analyzing the 2026 Pipeline Pivot and Recent Stock Surge
Via PredictStreet
Topics Economy Initial Public Offering Intellectual Property
News headline image
Genmab Stock Slips After Discontinuing Further Development Of Cancer Drug Developed With BioNTech ↗
Via Stocktwits
Topics Supply Chain
News headline image
Moderna (MRNA) Deep-Dive: Navigating the 7.5% Year-End Slide and the Path to a 2028 Recovery
Via PredictStreet
Topics Initial Public Offering
News headline image
The Pfizer Pivot: A Deep-Dive into PFE’s 2025 Financial Recovery and Strategic Rebirth
Via PredictStreet
Topics Economy Intellectual Property
News headline image
Moderna (MRNA): The “Act 2” of an mRNA Pioneer – A 2025 Deep Dive
Via PredictStreet
Topics Earnings Initial Public Offering Intellectual Property
News headline image
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
From BioNTech SE
Via GlobeNewswire
News headline image
Pfizer's Muted 2026 Outlook Sends Ripples Through Pharmaceutical Sector
Via MarketMinute
Topics Intellectual Property
News headline image
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Achieves Minimum Condition in CureVac Exchange Offer
From BioNTech SE
Via GlobeNewswire
News headline image
Moderna, BioNTech Slammed After FDA Links Covid Shots To 10 Deaths ↗
Via Investor's Business Daily
Topics Death
News headline image
2 Top Dividend Stocks to Buy and Hold ↗
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
BioNTech (BNTX) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration
From BioNTech SE
Via GlobeNewswire
News headline image
Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run ↗
Via Benzinga
News headline image
BioNTech Says Collaboration With Pfizer Going Strong After Report Indicated US Pharma Giant Considering Stake Sale In The German Company ↗
Via Stocktwits
News headline image
BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership ↗
Via Benzinga

Frequently Asked Questions

Is BioNTech SE - American Depositary Shares publicly traded?
Yes, BioNTech SE - American Depositary Shares is publicly traded.
What exchange does BioNTech SE - American Depositary Shares trade on?
BioNTech SE - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for BioNTech SE - American Depositary Shares?
The ticker symbol for BioNTech SE - American Depositary Shares is BNTX on the Nasdaq Stock Market
What is the current price of BioNTech SE - American Depositary Shares?
The current price of BioNTech SE - American Depositary Shares is 123.44
When was BioNTech SE - American Depositary Shares last traded?
The last trade of BioNTech SE - American Depositary Shares was at 01/22/26 10:16 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.